Merdad Parsey sold $2.3M of GILD
Chief Medical Officer at GILEAD SCIENCES, INC.. 25,590 shares at an average of $91.50, traded Nov 6, 2024, filed Nov 7, 2024.
Score components
- +15RoleOfficer
- +25Trade size$2.3M at market
- +5Share of holdings soldSold 20% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.9%, 3m +1.0%, 6m +1.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-24-026735, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2024 | MOption exercise Common Stock10b5-1 | +25,000 | $57.92 | $1.4M | 125,189 | Nov 7, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -20,590 | $91.50 | $1.9M | 104,599 | Nov 7, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -5,000 | $91.50 | $458k | 99,599 | Nov 7, 2024 |
| Nov 6, 2024 | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 121,670 | Nov 7, 2024 |
Related signals
Other insiders at GILEAD SCIENCES, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 34Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $436k 3,000 shares | -2% | |
| 27Weak | GILEAD SCIENCES, INC. | Johanna Mercier Chief Comm & Corp Aff Officer | $433k 3,000 shares | -3% | |
| 45Moderate | GILEAD SCIENCES, INC. | Daniel Patrick O'Day Chairman & CEO | $2.2M 15,000 shares | -3% | |
| 16Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $276k 2,500 shares | -1% | |
| 12Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $2.1M 17,929 shares | -10% | |
| 15Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $260k 2,500 shares | -1% | |
| 22Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $14M 137,676 shares | -45% | |
| 32Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $14M 142,180 shares | -52% | |
| 15Weak | GILEAD SCIENCES, INC. | Andrew D Dickinson Chief Financial Officer | $228k 2,500 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.